Rezolute, Inc. (RZLT)
Rezolute is a Redwood City pharmaceutical company developing ersodetug to treat low blood sugar caused by hyperinsulinism. It last closed at $3.92 on Nov 20, down 6.67% on the day. The next earnings report for RZLT is expected around Thu, Feb 11, 2027, after the close. For the quarter ended Sep 2026, RZLT reported EPS of -$0.18. Over its last 8 reports the stock moved an average of 4.8% the session after earnings. Over the last 12 months RZLT insiders bought $236K of stock on the open market and sold $0, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From RZLT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on RZLT
Technical AnalysisPrices may be delayed
The stock is 1% below its 20 day and 3% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is improving (RSI 48). The nearest support is the swing low (Oct 5) at $3.82, and the nearest resistance the 200 day average at $3.95.
| RSI (14) | 48.37 | Middle of its range | Neutral |
| MACD | -0.02 | Above its signal line | Bullish |
| Stochastic | 60.9 | Middle of its range | Neutral |
| ADX (14) | 15.8 | No clear trend | |
| Williams %R | -55.4 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 19.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +1.0% | Change over 10 sessions | Bullish |
| ATR (14) | $0.37 | Typical daily range, 9.5% of price |
| RSI (14) | 47.32 | Middle of its range | Neutral |
| MACD | -0.12 | Below its signal line | Bearish |
| Stochastic | 19.9 | Near the bottom of its range | Oversold |
| ADX (14) | 18.4 | No clear trend | |
| Williams %R | -75.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -78.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −7.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.79 | Typical daily range, 20.2% of price |
What happened before
See how RZLT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RZLT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options FlowPrices may be delayed
90DNo whale options trades in RZLT in the last 90 days.
RZLT Institutional Ownership
Full report →- ▼60 buying vs 76 selling
- ▼Held by funds -1.9 pts
- ▼Funds holding -8
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 138 | 146 | −5.5% |
| In funds' top 10 | 0 | 2 | −100.0% |
| Held by funds | 87.8% | 89.6% | −1.9 pts |
| New / increased | 18 / 42 | 39 / 60 | −39.4% |
| Reduced / sold out | 49 / 27 | 30 / 19 | +55.1% |
| Put/call ratio | 0.00 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
RZLT Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 30 | Daron EvansCFO | Buy | 10,000 | $2.85 | $29K |
| Dec 16, 2025 | Brian Kenneth RobertsChief Medical Officer | Buy | 28,000 | $1.70 | $48K |
| Dec 16, 2025 | Wladimir HogenhuisDirector | Buy | 5,650 | $1.69 | $10K |
| Dec 15, 2025 | Sunil Ratilal KarnawatChief Commercial Officer | Buy | 12,100 | $1.62 | $20K |
| Dec 15, 2025 | Nevan C ElamCEO | Buy | 32,000 | $1.59 | $51K |
| Dec 15, 2025 | Daron EvansCFO | Buy | 45,000 | $1.77 | $80K |
From SEC Form 4 filings by RZLT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RZLT is in one of them and how their past RZLT trades turned out.
RZLT News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RZLT in an article yet. Here's the latest on the wider market.
- Rezolute, Inc.: Still Holding Out For Ersodetug Approval - Which May Be Understandable
- Rezolute Announces Pricing of Approximately
- Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
- Rezolute Reports First Quarter Fiscal 2027 Financial
- A Late - stage Ultra - rare Disease Company Treating Refractory Hypoglycemia Corporate Presentation
About Rezolute
Rezolute is a pharmaceutical company based in Redwood City, California, that is developing treatments for hypoglycemia, or dangerously low blood sugar, caused by hyperinsulinism. Its main candidate, ersodetug, is an intravenously given antibody that acts on the insulin receptor to help bring blood glucose back into a more normal range. The company is studying the drug in children with congenital hyperinsulinism and in patients with tumor-related hyperinsulinism. Its work is aimed at patients and families affected by these rare conditions, for whom current treatment options are limited.
- Headquarters
- Redwood City, CA

